Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial

PURPOSE: The EUPHRATES trial examined the impact of polymyxin B hemoperfusion (PMX) on mortality in patients with septic shock and endotoxemia, defined as EAA ≥ 0.60. No difference was found in 28-day all-cause mortality. However, the trial showed that in some patients with septic shock the burden o...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, D. J., Foster, D., Walker, P. M., Bagshaw, S. M., Mekonnen, H., Antonelli, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280819/
https://www.ncbi.nlm.nih.gov/pubmed/30470853
http://dx.doi.org/10.1007/s00134-018-5463-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280819/
https://www.ncbi.nlm.nih.gov/pubmed/30470853
http://dx.doi.org/10.1007/s00134-018-5463-7

Ejemplares similares